Korsana Biosciences, Inc. (KRSA)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1755237 · fiscal year ends in Dec
Closing price $30.05 on 30 Oct 2026; 52-week range $7.56 to $44.66.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $1.9M
- Revenue growth
- -12.6%
- Net income, last twelve months
- -$6.7M
- Operating margin
- -359.2%
- Net margin
- -353.0%
- Return on equity
- -131.8%
- Market value
- $127.9M
- Cash
- $1.4M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 4.3M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $2.1M | -$5.0M | -$3.5M | -$1.11 | – | 10-K filed 30 Mar 2026 |
| FY2024 | 31 Dec 2024 | $2.0M | -$3.6M | -$3.1M | -$1.21 | – | 10-K filed 4 Mar 2025 |
| FY2023 | 31 Dec 2023 | $0 | -$13.0M | -$5.3M | -$2.25 | – | 10-K filed 5 Mar 2024 |
| FY2022 | 31 Dec 2022 | $297.0K | -$18.5M | -$44.1M | -$20.20 | -$40.6M | 10-K filed 22 Mar 2023 |
| FY2021 | 31 Dec 2021 | $3.9M | -$55.2M | -$51.6M | -$26.40 | -$36.5M | 10-K filed 24 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $0 | -$1.8M | -$0.41 |
| Q1 FY2026 | 31 Mar 2026 | $0 | -$3.2M | -$0.76 |
| Q4 FY2025 | 31 Dec 2025 | $1.0M | -$799.0K | -$0.14 |
| Q3 FY2025 | 30 Sep 2025 | $875.0K | -$976.0K | -$0.30 |
| Q2 FY2025 | 30 Jun 2025 | $93.0K | -$324.0K | -$0.11 |
| Q1 FY2025 | 31 Mar 2025 | $81.0K | -$1.4M | -$0.56 |
| Q4 FY2024 | 31 Dec 2024 | $1.8M | $530.0K | $0.23 |
| Q3 FY2024 | 30 Sep 2024 | $194.0K | -$723.0K | -$0.29 |
Company events
The newest 8-K filings of 70 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 11 Sep 2026 | 8-K | Change in control, Results, Deal completed, Leadership change, Material agreement, Share sale, Shareholder rights change, Bylaws or fiscal year change, Code of ethics change, Shell company status, Investor update | 1.01, 2.01, 2.02, 3.02, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06, 7.01, 9.01 |
| 27 Aug 2026 | 8-K | Shareholder vote, Other events | 5.07, 8.01, 9.01 |
| 25 Aug 2026 | 8-K | Other events | 8.01 |
| 1 Apr 2026 | 8-K | Change in control, Leadership change, Material agreement, Investor update | 1.01, 5.01, 5.02, 7.01, 9.01 |
| 17 Feb 2026 | 8-K | Investor update | 7.01, 9.01 |
| 6 Jan 2026 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 1 Dec 2025 | 8-K | Other events | 8.01 |
| 23 Sep 2025 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 18 Jun 2025 | 8-K | Shareholder vote | 5.07, 9.01 |
| 7 May 2025 | 8-K | Material agreement | 1.01, 9.01 |
| 25 Mar 2025 | 8-K | Material agreement, Share sale | 1.01, 3.02, 9.01 |
| 17 Dec 2024 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
Every filing
The newest filings with the SEC of 192 held.
| Filed | Form | Period |
|---|---|---|
| 15 Oct 2026 | DEF 14A | 13 Nov 2026 |
| 5 Oct 2026 | PRE 14A | 5 Oct 2026 |
| 11 Sep 2026 | 8-K | 8 Sep 2026 |
| 27 Aug 2026 | 8-K | 26 Aug 2026 |
| 25 Aug 2026 | 425 | – |
| 25 Aug 2026 | 8-K | 25 Aug 2026 |
| 12 Aug 2026 | 425 | – |
| 10 Aug 2026 | 425 | – |
| 6 Aug 2026 | 425 | – |
| 4 Aug 2026 | 10-Q | 30 Jun 2026 |
| 3 Aug 2026 | 425 | – |
| 24 Jul 2026 | EFFECT | – |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 22 Oct 2026 | MICHAEL HIGGINS, Director | 1,107 | $35.4K | 22 Oct 2026 |
| 23 Sep 2026 | ERROL B DE SOUZA, Director | 4,903 | $171.6K | 23 Sep 2026 |
| 22 Sep 2026 | ERROL B DE SOUZA, Director | 100 | $3.5K | 22 Sep 2026 |
| 18 Sep 2026 | ERROL B DE SOUZA, Director | 2,139 | $74.8K | 18 Sep 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 15 Oct 2026 | J. Wood Capital Advisors LLC | 13G amended | 0.1% | 26.0K |
| 7 Oct 2026 | FMR LLC | 13G amended | 6.9% | 3.1M |
| 18 Sep 2026 | GENERAL ATLANTIC, L.P. | 13G | 6.8% | 3.2M |
| 16 Sep 2026 | Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. | 13G | 6.1% | 2.8M |
| 15 Sep 2026 | Venrock Healthcare Capital Partners III, L.P. | 13D | 9.9% | 4.6M |
| 11 Sep 2026 | Fairmount Funds Management LLC | 13D | 19.99% | 9.1M |
| 14 Aug 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G | 7.33% | 317.5K |
| 14 Aug 2026 | ADAR1 Capital Management, LLC | 13G | 7% | 298.8K |
| 20 Jul 2026 | Peter M. Hecht | 13D amended | 19.4% | 910.2K |
| 7 May 2026 | FMR LLC | 13G | 15% | 649.5K |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 23.8K | +106.06% | 1 |
| 30 Sep 2026 | 11.6K | +160.06% | 1 |
| 15 Sep 2026 | 4.4K | -75.41% | 1 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.33T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $657.6B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $521.0B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $368.9B
- Novartis AG (NVS): revenue $54.5B, market value $306.8B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $289.5B
- Abbott Laboratories (ABT): revenue $46.6B, market value $183.8B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $178.6B
- Pfizer Inc. (PFE): revenue $63.7B, market value $173.8B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $141.6B